Business
Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes
Calgary, Alberta--(Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HM...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 DiabetesCalgary, Alberta--(Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (\"Hemostemix\" or the \"Company\") is pleased to announce it has signed a contract with Dr. James Shapiro, University of Alberta, Edmonton and will complete a transfer ACP-01 to Dr. Shapiro's laboratory. The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis in the heart and limbs of individuals who suffer from ischemia, and cell transplants from human islets or stem cells, hold huge promise in the treatment of diabetes. Following technology transfer, the team will create a new product by combining the two formulations, beginning with human islets. Thereafter, the team will complete preclinical studies to demonstrate the product's characteristics in vivo, with a plan to move forward with first-in-human testing.Professor James Shapiro led the clinical team with the \"Edmonton Protocol\" islet transplant success, and was lead author of the 2000 New England Journal of Medicine (\"NEJM\") study. He was the principal investigator of an international trial that replicated the Edmonton protocol study success, which was published in the NEJM in 2006. As principal investigator on several international islet transplant trial grants, Dr. Shapiro has brought in more than $85 million in grant and philanthropic support through the U of A for work on islet transplantation. He has been the recipient of multiple awards, including the Hunterian Medal from the Royal College of Surgeons of England, the Gold Medal in Surgery from the Governor General of Canada, Physician of the Century, and was named one of Nature Biotechnology's most remarkable and influential personalities. He was elected Fellow of the Royal Society of Canada in 2012, and was recently appointed as the Department of Surgery's first Canada Research Council's Chair in Transplantation Surgery and Regenerative Medicine.Professor Shapiro is a busy clinical hepatobiliary and pancreatic oncology and transplant surgeon, and also maintains an active immunology/transplant research laboratory. His group is actively researching personalized medicine approaches to pancreatic and other hepatobiliary cancers, with generation of human tum...